<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320501">
  <stage>Registered</stage>
  <submitdate>14/01/2010</submitdate>
  <approvaldate>6/06/2011</approvaldate>
  <actrnumber>ACTRN12611000577910</actrnumber>
  <trial_identification>
    <studytitle>Influence of hemodialysis, hemodiafiltration and peritoneal dialysis on asymmetric dimethylarginine and markers of oxidative stress</studytitle>
    <scientifictitle>Influence of hemodialysis, hemodiafiltration and peritoneal dialysis on asymmetric dimethylarginine and markers of oxidative stress in patients with chronic renal failure.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CRG030600046
Cochrane Renal Group</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>End stage renal disease</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Eight weeks of hemodialysis (HD, low-flux polysulfone membrane) versus eight weeks of on-line predilution hemodiafiltration (HDF, high-flux polysulfone membrane, susbstitution volume 200 mL/min)), duration of both HD and HDF was 4.5 hrs/session 3 times a week. Crossover study, 1 week break in between.</interventions>
    <comparator>Controls were volunteers without renal disease and without treatment. We studied baseline values of controls, 20 HD patients and 19 peritoenal dialysis patients. Then, randomly selected 16 HD patients were  randomized to crossover study, 8 started with HD, 8 with HDF.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in plasma levels of asymmetric dimethylarginine (ADMA), advanced glycation end-products and homocystein after a period of 8 weeks of hemodiafiltration or hemodialysis. This primary outcome is being done in patients with end stage renal disease.</outcome>
      <timepoint>after 8 weeks of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients: persons on maintenance hemodialysis or peritoneal dialysis for at least 3 months. Controls: healthy volunteers withou renal disease.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Unstable clinical condition, infection, malignancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence>Trial subjects for HD and HDF were randomised using simple randomisation (random numbers table)</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/06/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Research Project No. MSM 0021620819, Ministry of Health, Czech Republic.</primarysponsorname>
    <primarysponsoraddress>Ministry of Health, 
Palackeho square 4
128 01 Praha 2
Czech Republic</primarysponsoraddress>
    <primarysponsorcountry>Czech Republic</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Research Project No. MSM 0021620819, Ministry of Health, Czech Republic.</fundingname>
      <fundingaddress>Ministry of Health, 
Palackeho square 4
128 01 Praha 2
Czech Republic</fundingaddress>
      <fundingcountry>Czech Republic</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Increased ADMA levels in patients undergoing HD, as compared to PD, may be caused by higher oxidative stress and lower residual renal function in HD. Other
factors, such as diabetes and statin therapy, may also be at play. The decrease in ADMA at the end of HD and HDF
is comparable. Switching from HD to HDF decreases in 8 weeks the predialysis levels of homocysteine without affecting ADMA.</summary>
    <trialwebsite />
    <publication>Published in Artif Organs. 2010 May;34(5):420-5.
Asymmetric dimethylarginine in hemodialysis, hemodiafiltration, and peritoneal dialysis.
Eiselt J, Rajdl D, Racek J, Siroká R, Trefil L, Opatrná S.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics Commitee</ethicname>
      <ethicaddress>Medical School and Teaching Hospital Plzen
13 dr. E. Benese
301 00 Plzen
Czech Republic</ethicaddress>
      <ethicapprovaldate>26/02/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>26/01/2006</ethicsubmitdate>
      <ethiccountry>Czech Republic</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr, Jaromir, Eiselt</name>
      <address>Lecturer, Department of Internal Medicine I, Charles University, School of Medicine, Alej Svobody 80, 304 60, Plzen, Czech Republic</address>
      <phone>+420 377 103 925</phone>
      <fax>+420 377 103 920</fax>
      <email>eiselt@fnplzen.cz</email>
      <country>Czech Republic</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr, Jaromir, Eiselt</name>
      <address>Lecturer, Department of Internal Medicine I, Charles University, School of Medicine, Alej Svobody 80, 304 60, Plzen, Czech Republic</address>
      <phone>+420 377 103 925</phone>
      <fax>+420 377 103 920</fax>
      <email>eiselt@fnplzen.cz</email>
      <country>Czech Republic</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr, Jaromir, Eiselt</name>
      <address>Lecturer, Department of Internal Medicine I, Charles University, School of Medicine, Alej Svobody 80, 304 60, Plzen, Czech Republic</address>
      <phone>+420 377 103 925</phone>
      <fax>+420 377 103 920</fax>
      <email>eiselt@fnplzen.cz</email>
      <country>Czech Republic</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>